Compare PCRX & IIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | IIPR |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2010 | 2016 |
| Metric | PCRX | IIPR |
|---|---|---|
| Price | $36.48 | $52.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 7 |
| Target Price | $33.57 | ★ $62.15 |
| AVG Volume (30 Days) | ★ 958.5K | 257.8K |
| Earning Date | 11-09-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 14.33% |
| EPS Growth | ★ 107.44 | N/A |
| EPS | 0.89 | ★ 3.38 |
| Revenue | ★ $541,533,000.00 | $265,955,000.00 |
| Revenue This Year | $3.84 | N/A |
| Revenue Next Year | $4.73 | N/A |
| P/E Ratio | $40.96 | ★ $15.70 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $44.58 |
| 52 Week High | $36.67 | $65.38 |
| Indicator | PCRX | IIPR |
|---|---|---|
| Relative Strength Index (RSI) | 82.40 | 42.37 |
| Support Level | $22.00 | $48.98 |
| Resistance Level | $36.67 | $57.77 |
| Average True Range (ATR) | 0.04 | 1.47 |
| MACD | -0.37 | -0.17 |
| Stochastic Oscillator | 90.00 | 6.31 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Innovative Industrial Properties Inc is a real estate investment trust focused on the acquisition, ownership and management of specialized industrial and commercial properties in the United States. Its properties are prominently leased to state-licensed operators for their regulated cannabis facilities. The company conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by its Operating Partnership, directly or through subsidiaries. Its segments are: Cannabis Portfolio and Life Science Portfolio, with the majority of revenue coming from the Cannabis Portfolio segment, which involves acquiring, developing, and leasing real estate to regulated cannabis operators on long-term triple-net leases.